Clinical research
Esperion announced positive top-line results from the Phase 2 bempedoic acid / ezetimibe combination tablet study.
AstraZeneca announced positive results from the Phase III ETHOS trial for triple-combination therapy PT010 in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).
The TULIP 2 trial was the second Phase III trial that assessed the safety and efficacy of anifrolumab as a treatment for adults with moderate-to-severe SLE.
Company’s insulin-based Imotope™ IMCY-0098 shows excellent safety profile and promising clinical trends while eliciting immune responses supporting the proposed mode of action
Successful validation of standardized clinical procedure for instillation of nanoparticles in first patient cohort
This study aimed to determine the appropriate dose for Japanese patients treated with lurbinectedin, in monotherapy, for advanced solid tumors.
Breztri Aerosphere is a triple combination drug of budesonide, glycopyrronium and formoterol fumarate.
Santhera Pharmaceuticals announces publication by ReveraGen of positive study data with vamorolone in patients with Duchenne muscular dystrophy.
Inclisiran is a PCSK9 inhibitor, a class of anti-cholesterol medications used to treat patients who don’t respond to statins.
The investigational JAK inhibitor has hit the mark in three late-stage studies, with readouts from two more late-stage trials expected later this year.
PRESS RELEASES